

In the Claims:

1. (Currently Amended) A depot system, for delayed release of active substances comprising liposomes having a membrane the liposomes comprising

saturated synthetic phosphatidyl cholines selected from one or more from the group consisting of ~~DMPC~~ dimyristoyl phosphatidylcholine (DMPC), ~~DPPC~~ dipalmitoyl phosphatidylcholine (DPPC) and ~~DSPC~~ distearoyl phosphatidylcholine (DSPC),

cholesterol and/or derivatives with a percentage ranging from about 35 to about 50 mole-%,

cationic lipids selected from the group of ~~DC-Chol~~ 3-β-[N-(N',N'-dimethylaminoethane)carbamoyl]cholesterol (DC-Chol), ~~DAC-Chol~~ 3-β-[N-(N',N'-dimethylaminoethane)carbamoyl]cholesterol (DAC-Chol), ~~DMTAP~~ N-[1-(2,3-dimyristoyloxy)propyl]-N, N, N-trimethylammonium salt (DMTAP), ~~DPTAP~~ N-[1-(2,3-dipalmitoyloxy)propyl]-N, N, N-trimethylammonium salt (DPTAP) and ~~DOTAP~~ N-[1-(2,3-dioleoyloxy)propyl]-N, N, N-trimethylammonium salt (DOTAP) with a percentage ranging from 5 to 20 mole-% in the liposomal membrane, and

one or more selected active substances from the group consisting of protein and peptide active substances.

2. (Withdrawn) The depot system according to claim 1, wherein the cationic lipids are cationic in a pH-sensitive fashion and selected from one or more from the group consisting of histaminylcholesterol hemisuccinate (His-Chol) and morpholine-N-ethylamino cholesterol (Mo-Chol).

3. (Previously Presented) The depot system according claim 1, wherein at least about 90% of the active substance is enclosed in the liposome and less than about 10% is outside the liposome.

4. (Previously Presented) The depot system according to claim 1, wherein the active substance is entrapped in the liposome and more than about 10% thereof is outside the liposome.

5. (Previously Presented) The depot system according to claim 1, wherein the depot

system is capable of sustaining the delivery of the active substance for at least 1 week.

6. (Previously Presented) The depot system according to claim 1, wherein the size of the liposomes varies from about 20 to about 1,000 nm.

7. - 18. (CANCELLED)

19. (Previously Presented) The depot system according to claim 1, wherein the size of the liposomes varies from about 50 to about 800 nm.

20. (Previously Presented) The depot system according to claim 1, wherein the size of the liposomes varies from about 50 to about 300 nm.

21. (Previously Presented) The depot system according to claim 1, wherein the active substance comprises one or more from the group consisting of LHRH agonists and GnRH analogs.

22. (Previously Presented) The depot system according to claim 21, wherein the active substance comprises one or more from the group consisting of leuprolide, acetate, buserelin, goserelin and triptorelin.

23. (Withdrawn) The depot system according to claim 1, wherein the said active substance comprises insulin.

24. (Withdrawn) The depot system according to claim 1, wherein the said active substance comprises heparin.

25. (Withdrawn) The depot system according to claim 1, wherein said active substance comprises antigen fragments for vaccination.

26. (Withdrawn) The depot system according to claim 1, wherein the depot system is

capable of a delayed release of active substance for at least one week and said active substance comprises oligonucleotides.

27. (Withdrawn) The depot system according to claim 26, wherein said oligonucleotides are constituted of 5-100 from the group consisting of deoxyribonucleotides, ribonucleotides and chemically modified derivatives thereof.

28. (Withdrawn) The depot system according to claim 26, wherein said oligonucleotides are constituted of 5-40 from the group consisting of deoxyribonucleotides, ribonucleotides and chemically modified derivatives thereof.

29. (Withdrawn) The depot system according to claim 26, wherein said oligonucleotides are constituted of 10-25 from the group consisting of deoxyribonucleotides, ribonucleotides and chemically modified derivatives thereof.

30. (Withdrawn) The depot system according to claim 26, wherein said oligonucleotides are present as one or more from the group consisting of a single strand, a double strand and in complex folding.

31. (Withdrawn) The depot system according to claim 30, wherein said oligonucleotides are present as a single strand, said single strand being present as antisense oligonucleotides.

32. (Withdrawn) The depot system according to claim 30, wherein said oligonucleotides are present as a double strand, said double strand being present as small interfering RNA, decoy oligonucleotides.

33. (Withdrawn) The depot system according to claim 30, wherein said oligonucleotides are present in complex folding as aptamers, spieglemers.

34. (Withdrawn) The depot system according to claim 1, wherein the depot system is capable of a delayed release of active substance for at least one week and said active substance

comprises a water-soluble active substance derivative selected from one or more from the group consisting of active substances of antibiotic, antimycotic, cytostatic agents and glucocorticoids.

35. (Previously Presented) Method of administering the depot system according to claim 1, comprising the step of injecting the depot system subcutaneously or intramuscularly.

36. (Withdrawn) Method of administering the depot system according to claim 1, comprising the step of one or both from the group consisting of topical and local application to support healing processes.

37. (Previously Presented) A Drug comprising a depot system according to claim 1.

38. (New) A method of using liposomes as depot system for the delayed release of active substances comprising the steps of

providing liposomes having a size of between about 20 – 1000 nm, said liposomes comprising at least one active substance, wherein the composition of the liposomes comprises at least one saturated phospholipid, at least one cholesterol, and
at least one cationic or pH sensitive cationic lipid.

39. (New) The method according to claim 38, wherein said at least one active substance is selected from the group consisting of peptide and proteins.

40. (New) The method according to claim 38, wherein said at least one saturated phospholipid is selected from one or more from the group consisting of dimyristoyl phosphatidylcholine (DMPC), dipalmitoyl phosphatidylcholine (DPPC) and distearoyl phosphatidylcholine (DSPC), and wherein said said cationic lipid is selected from one or more from the group consisting of 3- β -[N-(N',N'-dimethylaminoethane)carbamoyl]cholesterol (DC-Chol), 3- β -[N-(N',N'-dimethylaminoethane)carbamoyl]cholesterol DAC-Chol, N-[1-(2,3-dimyristoyloxy)propyl]-N, N, N-trimethylammonium salt (DMTAP), N-[1-(2,3-dipalmitoyloxy)propyl]-N, N, N-trimethylammonium salt (DPTAP) and N-[1-(2,3-dioleoyloxy)propyl]-N, N, N-trimethylammonium salt (DOTAP).

41. (New) The method according to claim 38, wherein at least about 90% of said at least one active substance is enclosed in the liposome and less than about 10% is outside the liposome.

42. (New) The method according to claim 38, wherein the active substance is entrapped in the liposome and more than about 10% thereof is outside the liposome.

43. (New) The method according to claim 38 comprising the step of injecting the depot system subcutaneously or intramuscularly.